RATIONALE: Th17 cells comprise a distinct lineage of proinflammatory T helper cells that are major contributors to allergic responses. It is unknown whether cyclooxygenase (COX)-derived eicosanoids regulate Th17 cells during allergic lung inflammation. OBJECTIVES: To determine the role of COX metabolites in regulating Th17 cell differentiation and function during allergic lung inflammation. METHODS: COX-1(-/-), COX-2(-/-), and wild-type mice were studied in an in vivo model of ovalbumin-induced allergic inflammation and an in vitro model of Th17 differentiation using flow cytometry, cytokine assays, confocal microscopy, real-time polymerase chain reaction, and immunoblotting. In addition, the role of specific eicosanoids and their receptors was examined using synthetic prostaglandins (PGs), selective inhibitors, and siRNA knockdown. MEASUREMENTS AND MAIN RESULTS: Th17 cell differentiation in lung, lymph nodes, and bronchoalveolar lavage fluid was significantly lower in COX-2(-/-) mice after ovalbumin sensitization and exposure in vivo. In vitro studies revealed significantly impaired Th17 cell differentiation of COX-2(-/-) naive CD4(+) T cells with decreased Stat3 phosphorylation and RORγt expression. Synthetic PGF(2α) and PGI(2) enhanced Th17 cell differentiation of COX-2(-/-) CD4(+) T cells in vitro. The selective COX-2 inhibitor, NS-398, and PGF(2α) receptor and PGI(2) receptor siRNA knockdown significantly decreased Th17 cell differentiation in vitro. Administration of synthetic PGs restored accumulation of Th17 cells in lungs of allergic COX-2(-/-) mice in vivo. CONCLUSIONS: COX-2 is a critical regulator of Th17 cell differentiation during allergic lung inflammation via autocrine signaling of PGI(2) and PGF(2α) through their respective cell surface receptors.
RATIONALE: Th17 cells comprise a distinct lineage of proinflammatory T helper cells that are major contributors to allergic responses. It is unknown whether cyclooxygenase (COX)-derived eicosanoids regulate Th17 cells during allergic lung inflammation. OBJECTIVES: To determine the role of COX metabolites in regulating Th17 cell differentiation and function during allergic lung inflammation. METHODS:COX-1(-/-), COX-2(-/-), and wild-type mice were studied in an in vivo model of ovalbumin-induced allergic inflammation and an in vitro model of Th17 differentiation using flow cytometry, cytokine assays, confocal microscopy, real-time polymerase chain reaction, and immunoblotting. In addition, the role of specific eicosanoids and their receptors was examined using synthetic prostaglandins (PGs), selective inhibitors, and siRNA knockdown. MEASUREMENTS AND MAIN RESULTS: Th17 cell differentiation in lung, lymph nodes, and bronchoalveolar lavage fluid was significantly lower in COX-2(-/-) mice after ovalbumin sensitization and exposure in vivo. In vitro studies revealed significantly impaired Th17 cell differentiation of COX-2(-/-) naive CD4(+) T cells with decreased Stat3 phosphorylation and RORγt expression. Synthetic PGF(2α) and PGI(2) enhanced Th17 cell differentiation of COX-2(-/-) CD4(+) T cells in vitro. The selective COX-2 inhibitor, NS-398, and PGF(2α) receptor and PGI(2) receptor siRNA knockdown significantly decreased Th17 cell differentiation in vitro. Administration of synthetic PGs restored accumulation of Th17 cells in lungs of allergic COX-2(-/-) mice in vivo. CONCLUSIONS:COX-2 is a critical regulator of Th17 cell differentiation during allergic lung inflammation via autocrine signaling of PGI(2) and PGF(2α) through their respective cell surface receptors.
Authors: Timothy J Harris; Joseph F Grosso; Hung-Rong Yen; Hong Xin; Marcin Kortylewski; Emilia Albesiano; Edward L Hipkiss; Derese Getnet; Monica V Goldberg; Charles H Maris; Franck Housseau; Hua Yu; Drew M Pardoll; Charles G Drake Journal: J Immunol Date: 2007-10-01 Impact factor: 5.422
Authors: Kinga Majchrzak; Michelle H Nelson; Jacob S Bowers; Stefanie R Bailey; Megan M Wyatt; John M Wrangle; Mark P Rubinstein; Juan C Varela; Zihai Li; Richard A Himes; Sherine Sl Chan; Chrystal M Paulos Journal: JCI Insight Date: 2017-04-20
Authors: Allison E Norlander; Melissa H Bloodworth; Shinji Toki; Jian Zhang; Weisong Zhou; Kelli Boyd; Vasiliy V Polosukhin; Jacqueline-Yvonne Cephus; Zachary J Ceneviva; Vivek D Gandhi; Nowrin U Chowdhury; Louis-Marie Charbonnier; Lisa M Rogers; Janey Wang; David M Aronoff; Lisa Bastarache; Dawn C Newcomb; Talal A Chatila; R Stokes Peebles Journal: J Clin Invest Date: 2021-04-01 Impact factor: 14.808
Authors: Madison G Boswell; Weisong Zhou; Dawn C Newcomb; R Stokes Peebles Journal: Prostaglandins Other Lipid Mediat Date: 2011-08-12 Impact factor: 3.072
Authors: Hong Li; Matthew L Edin; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Artiom Gruzdev; Jennifer Cheng; Ryan T Dackor; Ping Ming Wang; Carl D Bortner; Stavros Garantziotis; Anton M Jetten; Darryl C Zeldin Journal: Am J Respir Crit Care Med Date: 2013-04-15 Impact factor: 21.405
Authors: Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-24 Impact factor: 4.254
Authors: Weisong Zhou; Jian Zhang; Kasia Goleniewska; Daniel E Dulek; Shinji Toki; Dawn C Newcomb; Jacqueline Y Cephus; Robert D Collins; Pingsheng Wu; Mark R Boothby; R Stokes Peebles Journal: J Immunol Date: 2016-07-25 Impact factor: 5.422
Authors: Hong Li; Matthew L Edin; Artiom Gruzdev; Jennifer Cheng; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Darryl C Zeldin Journal: Prostaglandins Other Lipid Mediat Date: 2012-11-28 Impact factor: 3.072